Late Breaking Abstract - Long-term durability of ivacaftor (IVA) treatment benefit in people with cystic fibrosis (PwCF)

C. Merlo (Baltimore, United States), C. Scirica (Boston, United States), T. Thorat (Boston, United States), L. Mcgarry (Boston, United States), M. Dersarkissian (Los Angeles, United States), C. Nguyen (Los Angeles, United States), Y. Gu (Los Angeles, United States), A. Muthukumar (Los Angeles, United States), J. Healy (Boston, United States), M. Brookhart (Durham, United States), J. Rubin (Boston, United States)

Source: International Congress 2022 – Physiologic studies of respiratory diseases
Session: Physiologic studies of respiratory diseases
Session type: Thematic Poster
Number: 2765

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Merlo (Baltimore, United States), C. Scirica (Boston, United States), T. Thorat (Boston, United States), L. Mcgarry (Boston, United States), M. Dersarkissian (Los Angeles, United States), C. Nguyen (Los Angeles, United States), Y. Gu (Los Angeles, United States), A. Muthukumar (Los Angeles, United States), J. Healy (Boston, United States), M. Brookhart (Durham, United States), J. Rubin (Boston, United States). Late Breaking Abstract - Long-term durability of ivacaftor (IVA) treatment benefit in people with cystic fibrosis (PwCF). 2765

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.